GlassScriptPhysician profile
Joseph Krakowiak
NPI 1518316041
$1,944.60
in general payments reported to CMS, 2019-2025
25 companies · $389 in 2025
The $389 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $432 · 2023: $545 · 2024: $578 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,512.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $345.58 | 2022-2025 | Dovato, Cabenuva |
| Merck Sharp & Dohme LLC | $212.41 | 2022-2025 | Pifeltro, Delstrigo, Verquvo |
| Astrazeneca Pharmaceuticals LP | $191.67 | 2022-2025 | Farxiga, Breztri |
| Abbvie INC. | $142.74 | 2022-2025 | |
| Novo Nordisk INC | $138.00 | 2022-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $121.78 | 2022-2024 | Mounjaro |
| Exact Sciences Corporation | $102.50 | 2023-2024 | Cologuard Collection Kit |
| Theratechnologies INC. | $102.08 | 2022-2023 | Trogarzo, Egrifta |
| Bayer Healthcare Pharmaceuticals INC. | $79.51 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $59.89 | 2022 | |
| Glaxosmithkline, LLC. | $54.07 | 2023-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Gilead Sciences, INC. | $48.72 | 2023-2025 | Epclusa |
| Novartis Pharmaceuticals Corporation | $42.14 | 2023 | |
| Amgen INC. | $41.52 | 2022 | |
| Dexcom, INC. | $33.82 | 2022-2023 | Dexcom G6 Transmitter |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $33.77 | 2023-2024 | Rexulti |
| Esperion Therapeutics, INC. | $31.04 | 2024 | Nexletol |
| Pfizer INC. | $26.48 | 2024 | |
| Organon LLC | $26.41 | 2025 | Nexplanon |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.02 | 2024 | Caplyta |
| Janssen Biotech, INC. | $20.90 | 2023 | Symtuza |
| Abbott Laboratories | $19.12 | 2022 | |
| Alkermes, INC. | $17.84 | 2022 | |
| Phathom Pharmaceuticals, INC. | $16.22 | 2024 | Voquezna |
| Corcept Therapeutics | $15.37 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Krakowiak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.